IMPEDIMED LIMITED — Board/Management Information 2013

Oct 7, 2013

ASX ANNOUNCEMENT

==> picture [81 x 92] intentionally omitted <==

8[th] October 2013

IMPEDIMED APPOINTS ITS SECOND US DIRECTOR

• ImpediMed founder and long time chairman, Mel Bridges, retires

• David Adams to join ImpediMed board at AGM.

Brisbane, Australia – ImpediMed Limited (ASX IPD) (“ImpediMed”) announces the appointment of a second US Director to the Board, consistent with the release in May 2013.

David Adams will join the ImpediMed Board at the AGM on 11[th] November 2013 upon the retirement of founding chairman Mel Bridges.

”Dave’s prior experience as Vice President of Integration and Divestitures for Medtronic, Inc., where he focused extensively on acquisitions and integrations, as well as his knowledge and experience in legal, tax, M&A ventures and strategic planning will assist us in expanding our business and securing our resources for the future,” said Dr. Cherrell Hirst AO, Chairman of the Board.

“I am excited about the opportunity to work with ImpediMed to unlock the true value of ImpediMed’s business model, Intellectual Property and partnerships,” said Adams.

Mr. Adams held previous roles at Medtronic as Vice President, Cardiovascular Business Development; Vice President Vascular Business Development and Ventures, as well as management roles in financial planning and analysis. He holds a B.S. in Accountancy from the University of Illinois and a Juris Doctorate from William Mitchell College of Law.

“As we welcome Dave to the board, we farewell company founder and previous Chairman Mel Bridges. ImpediMed pays tribute to Mel for his long involvement and commitment to ImpediMed and especially for his services as Chairman of the Board for many years. As founder and a significant investor, Mel will always be part of ImpediMed and can be counted on to continue his strong support for the company and its health and business goals. Mel has for many years played a leading role in the Australian biotechnology industry and we are confident that the industry will continue to benefit from his contribution,” said Dr. Cherrell Hirst AO.

For further information contact:

Dr. Cherrell Hirst AO, ImpediMed Chairman T: +61(7)3860 3700 M: +61 411556124 Richard Carreon, ImpediMed CEO T: +1 (760) 585-2100

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.Impedimed.com.au